Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851005 | 0.89 | ITGA4 (0.53) | ITGA4L3MBTL1ITGB1ITGB7HCRTR1 | |
| SCHEMBL6712256 | 0.88 | ITGA4 (0.52) | ITGA4L3MBTL1ITGB1ITGB7HCRTR1 | |
| SCHEMBL3851934 | 0.87 | ITGA4 (0.41) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5609145 | 0.86 | ITGA4 (0.42) | ITGA4ITGB1ITGB7HCRTR1HCRTR2 | |
| SCHEMBL3849986 | 0.82 | ITGA4 (0.49) | ITGA4ITGB1ITGB7HCRTR1HCRTR2 | |
| SCHEMBL6709419 | 0.82 | ITGA4 (0.51) | ITGA4L3MBTL1ITGB1ITGB7HCRTR1 | |
| SCHEMBL3856300 | 0.82 | ITGB1 (0.48) | ITGA4ITGB1ITGB7HCRTR1HCRTR2 | |
| SCHEMBL7066750 | 0.82 | FKBP1A (0.58) | ITGA4L3MBTL1ITGB1RAB9AFKBP1A | |
| SCHEMBL7319786 | 0.82 | ITGA4 (0.54) | ITGA4L3MBTL1ITGB1ITGB7MAPT | |
| SCHEMBL3850647 | 0.81 | ITGB1 (0.51) | ITGA4ITGB1ITGB7HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGA4 3/4885L3MBTL1 4523/4885ITGB1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.